文献速递核素与放射性配体治疗肿瘤 PET/CT

肽受体放射性核素治疗联合替莫唑胺±卡培他滨治疗[18F]FDG阳性转移性神经内分泌肿瘤

Peptide receptor radionuclide therapy alone or in combination with temozolomide plus/minus capecitabine in [18F]FDG-positive metastatic neuroendocrine tumors.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-10-21

本研究回顾性纳入24例[18F]FDG阳性转移性神经内分泌肿瘤患者,分别接受[177Lu]Lu-DOTATATE单药、联合替莫唑胺(TEM)或联合CAPTEM方案。结果显示PRRT联合CAPTEM组客观缓解率和疾病控制率最高,且未增加毒性。

要点

  • PRRT联合CAPTEM在[18F]FDG阳性mNET中显示最高缓解率。
  • 联合治疗与PRRT单药相比未见毒性增加。
  • 需进一步研究确认联合方案对生存结局的附加价值。

核心结论

  • PRRT联合CAPTEM是[18F]FDG阳性mNET中最有前景的方案,缓解率高于PRRT单药或PRRT联合TEM。

研究设计与样本

  • 单中心回顾性研究,最终分析纳入24例[18F]FDG阳性mNET患者。
  • 患者接受[177Lu]Lu-DOTATATE 7.4 GBq单药或联合TEM(200 mg/kg/5d)±CAP(1500 mg/kg/14d)。

主要发现

  • 三组基线临床病理特征无差异;胰腺原发占58%,92%患者肝转移超过3个。
  • 组1(PRRT单药)基于[68Ga]Ga-DOTATOC PET/CT和ceCT的ORR为10%、DCR为50%,[18F]FDG PET/CT显示2例缓解(1例CR,1例PR)。
  • 组2(PRRT+TEM)ORR为14%、DCR为43%,[18F]FDG PET/CT显示2例缓解(1例CR,1例PR)。
  • 组3(PRRT+CAPTEM)ORR和DCR均为71%,[18F]FDG PET/CT显示5例缓解(3例CR,2例PR)。
  • 组3中位随访31个月时,4/7患者未进展,5/7患者仍存活。

关键数值与推荐

  • ORR和DCR基于[68Ga]Ga-DOTATOC PET/CT和ceCT评估。
  • 不良事件按CTCAE v5.0分类收集。

临床怎么用

  • 对于[18F]FDG阳性mNET,可考虑PRRT联合CAPTEM以提高缓解率。
  • 联合治疗未显示毒性增加,但需进一步研究确认生存获益。

局限性

  • 样本量小(24例),为单中心回顾性研究。
  • 需进一步研究确认联合方案对生存结局的附加价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent data demonstrate that one possibility for increasing Peptide Receptor Radionuclide Therapy (PRRT) results lies in the combination of PRRT with chemotherapy. This study aimed to evaluate response and outcome in [18F]FDG-positive metastatic neuroendocrine tumor (mNET) patients treated with PRRT alone or in combination with temozolomide (TEM) plus/minus capecitabine (CAP). METHODS: All mNET patients presented with [18F]FDG-positive disease prior to treatment (or retreatment) with PRRT alone or in combination with chemotherapy were retrospectively included in this single-center study. Patients received [177Lu]Lu-DOTATATE with an activity of 7.4 GBq alone or combined with TEM (200 mg/kg/5d) plus/minus CAP (1500 mg/kg/14d). Contrast-enhancement CT (ceCT), [68Ga]Ga-DOTATOC and [18F]FDG PET/CT studies were performed at baseline, after treatment, and every 6 months thereafter. Overall response rate (ORR) and disease control rate (DCR) were calculated for each group. Survival analysis was performed using the Kaplan-Meier method. Adverse events were collected and classified according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. RESULTS: A total of 24 patients were included in the final analysis. Group 1 received PRRT with [177Lu]Lu-DOTATATE alone (n = 10), group 2 received [177Lu]Lu-DOTATATE plus TEM (n = 7), and group 3 received [177Lu]Lu-DOTATATE plus CAPTEM (n = 7). There were no differences between groups in terms of clinicopathological features before treatment. The pancreas was the primary tumor site in 58%, and 92% of patients had more than three liver metastases. Based on [68Ga]Ga-DOTATOC PET/CT and ceCT, in group 1 the ORR and DCR were 10% and 50%, respectively. [18F]FDG PET/CT showed 2 responders (1 CR, 1 PR). In group 2, the ORR and DCR were 14% and 43%, respectively. [18F]FDG PET/CT showed 2 responders (1 CR, 1 PR). In group 3, the ORR and DCR were 71%, respectively. [18F]FDG PET/CT showed 5 responders (3 CR, 2 PR). In the latter group, 4/7 patients had not progressed and 5/7 were still alive at the time of analysis after a median follow-up of 31 months. CONCLUSION: Our results show PRRT combined with CAPTEM as the most promising regimen, achieving higher response rates in [¹⁸F]FDG-positive mNETs compared with PRRT alone or PRRT plus TEM. Further studies are required to confirm its added value in terms of survival outcomes. No increased toxicity seems to be associated with combination therapy compared to PRRT alone.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. di Santo G, Santo G, Wirth L, et al. Peptide receptor radionuclide therapy alone or in combination with temozolomide plus/minus capecitabine in [18F]FDG-positive metastatic neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2025. PMID: 41117982. doi:10.1007/s00259-025-07606-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。